Patient-reported outcome measure for central disorders of hypersomnolence (PROM-CDH): development and validation
Sleep Medicine · 2025
DOI: 10.1016/j.sleep.2025.106589 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Sleep Medicine, 2025. Verfasst von Denise Bijlenga und 4 weiteren Autor:innen. Beteiligte Einrichtung: Stichting Epilepsie Instellingen Nederland (SEIN), Sleep-Wake Center, Achterweg 3, 2103, SW, Heemstede, Netherlands; Leiden University Medical Center…. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Quality of Life, Disorders of Excessive Somnolence. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
STUDY OBJECTIVES: Central disorders of hypersomnolence (CDH) have a major impact on patients' quality of life (QoL). We developed and validated a disease-specific patient-reported outcome measure (PROM) to measure QoL in CDH: the PROM-CDH, for adults with narcolepsy types 1 and 2 (NT1 and NT2), and idiopathic hypersomnia (IH). METHODS: The developmental process involved focus groups and interviews with adults with CDH (n = 27), family members (n = 8) and sleep medicine specialists (n = 5). In the quantitative evaluation, the draft version of the PROM-CDH, together with the Epworth Sleepiness Scale (ESS), Fatigue Severity Scale (FSS), Hospital Anxiety and Depression Scale (HADS), ADHD rating scale (ADHD-RS) and the 36-item Short Form (SF-36) were filled out online by N = 369 patients with (suspected) CDH. RESULTS: Internal consistency was good for the total group and within diagnostic groups (all Cronbach's α > .8). Age was positively (β = .11; p = .003), and female gender (β = -3.67; p = .002), comorbid sleep apnea (β = -4.77; p = .005), and depression (β = -12.71; p < .001) were negatively associated with the PROM-CDH score. Exploratory and confirmatory factor analyses resulted in five subscales. Convergent validity showed highest correlation between the PROM-CDH total score and HADS Depression (r = -.71; p < .01); and the SF-36 subscales Emotional wellbeing (r = .65; p < .01) and Energy/fatigue (r = .71; p < .01). Additional adjustments including content validity in consensus rounds resulted in the final PROM-CDH (version 1, 2023). CONCLUSIONS: The PROM-CDH has high potential in clinical practice for patients with CDH, to support clinical care, as an important outcome in clinical trials, and as a sleep care quality indicator. Further international validation is ongoing, and it is freely available in multiple languages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Stichting Epilepsie Instellingen Nederland (SEIN), Sleep-Wake Center, Achterweg 3, 2103, SW, Heemstede, Netherlands; Leiden University Medical Center (LUMC), Department of Neurology, Albinusdreef 2, 2333, ZA, Leiden, Ne…
- Leiden University Medical Center (LUMC), Department of Neurology, Albinusdreef 2, 2333, ZA, Leiden, Netherlands; Stichting Dutch Institute for Clinical Auditing (DICA), Rijnsburgerweg 10, 2333, AA, Leiden, Netherlands.
Zitieren
APA
Bijlenga, D., De Boer, J., Fronczek, R., Tiemensma, J., & Lammers, G. J. (2025). Patient-reported outcome measure for central disorders of hypersomnolence (PROM-CDH): development and validation. Sleep Medicine. https://doi.org/10.1016/j.sleep.2025.106589
Vancouver
Bijlenga D, De Boer J, Fronczek R, Tiemensma J, Lammers GJ. Patient-reported outcome measure for central disorders of hypersomnolence (PROM-CDH): development and validation. Sleep Medicine. 2025. doi:10.1016/j.sleep.2025.106589
BibTeX
@article{Bijlenga2025,
author = {Bijlenga, Denise and De Boer, Josephine and Fronczek, Rolf and Tiemensma, Jitske and Lammers, Gert Jan},
title = {Patient-reported outcome measure for central disorders of hypersomnolence (PROM-CDH): development and validation},
journal = {Sleep Medicine},
year = {2025},
doi = {10.1016/j.sleep.2025.106589}
}
EUVIMED